their catalytic potential in acylation reactions of alcohols. The ability of the substitution pattern to stabilize acylpyridinium cations, which act as critical intermediates in the catalytic cycle of pyridine-catalyzed acylation reactions, has been assessed at the MP2(FC)/6-31+G(2d,p)//B98/6-31G(d) level of theory and inclusion of solvent effects in chloroform using the PCM continuum solvation model
Pyrazole compound and medicinal composition containing the same
申请人:Ohi Norihito
公开号:US20050261339A1
公开(公告)日:2005-11-24
The present invention provides a novel compound having an excellent JNK inhibitory effect. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them.
Wherein R
1
designates —(CO)
h
—(NR
a
)
j
—(CR
b
═CR
c
)
k
—Ar (wherein R
a
, R
b
and R
c
each independently designate a hydrogen atom, a halogen atom, hydroxyl group, an optionally substituted C
1-6
alkyl group or the like;
Cy designates a 5- or 6-membered heteroaryl; and
V each independently designate the formula -L-X—Y (wherein L designates a single bond, an optionally substituted C
1-6
alkylene group or the like; X designates a single bond or the formula -A- (wherein A designates NR
2
, O, CO, S, SO or SO
2
) and so on; and Y designates a hydrogen atom, a halogen atom, nitro group or the like).
Pyrazole compounds and pharmaceutical compositions comprising the compound
申请人:Ohi Norihito
公开号:US20050208582A1
公开(公告)日:2005-09-22
The present invention provides a novel compound having an excellent JNK inhibitory effect. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them.
Wherein R
1
designates —(CO
h
—(NR
a
)
j
—(CR
b
═CR
c
)
k
—Ar (wherein R
a
, R
b
and R
c
each independently designate a hydrogen atom, a halogen atom, hydroxyl group, an optionally substituted C
1-6
alkyl group or the like;
Cy designates a 5- or 6-membered heteroaryl; and
V each independently designate the formula -L-X—Y (wherein L designates a single bond, an optionally substituted C
1-6
alkylene group or the like; X designates a single bond or the formula -A- (wherein A designates NR
2
, O, CO, S, SO or SO
2
) and so on; and Y designates a hydrogen atom, a halogen atom, nitro group or the like).
PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND
申请人:Ohi Norihito
公开号:US20090054397A1
公开(公告)日:2009-02-26
The present invention provides a novel compound having an excellent JNK inhibitory effect. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them.
Wherein R
1
designates —(CO)
h
—(NR
a
)
j
—(CR
b
═CR
c
)
k
—Ar (wherein R
a
, R
b
and R
c
each independently designate a hydrogen atom, a halogen atom, hydroxyl group, an optionally substituted C
1-6
alkyl group or the like;
Cy designates a 5- or 6-membered heteroaryl; and
V each independently designate the formula -L-X—Y (wherein L designates a single bond, an optionally substituted C
1-6
alkylene group or the like; X designates a single bond or the formula -A- (wherein A designates NR
2
, O, CO, S, SO or SO
2
) and so on; and Y designates a hydrogen atom, a halogen atom, nitro group or the like).
PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME
申请人:Eisai Co., Ltd.
公开号:EP1510516A1
公开(公告)日:2005-03-02
The present invention provides a novel compound having an excellent JNK inhibitory effect. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them.
Wherein R1 designates -(CO)h-(NRa)j-(CRb=CRc)k-Ar (wherein Ra, Rb and Rc each independently designate a hydrogen atom, a halogen atom, hydroxyl group, an optionally substituted C1-6 alkyl group or the like;
Cy designates a 5- or 6-membered heteroaryl; and
V each independently designate the formula -L-X-Y (wherein L designates a single bond, an optionally substituted C1-6 alkylene group or the like; X designates a single bond or the formula -A- (wherein A designates NR2, O, CO, S, SO or SO2) and so on; and Y designates a hydrogen atom, a halogen atom, nitro group or the like).